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Abstract
OBJECTIVES—The Lynch syndrome (LS) is an inherited cancer syndrome showing a
preponderance of colorectal cancer (CRC) in context with endometrial cancer and several other
extracolonic cancers, which is due to pathogenic mutations in the mismatch repair (MMR) genes,
MLH1, MSH2, MSH6, and PMS2. Some families were found to show a LS phenotype without an
identified MMR mutation, although there was microsatellite instability and absence of MSH2
expression by immunohistochemistry. Studies of a subset of these families found a deletion at the
3′ end of the epithelial cell adhesion molecule (EPCAM) gene, causing transcription read-through
resulting in silencing of MSH2 through hypermethylation of its promoter. The tumor spectrum of
such families appears to differ from classical LS.
METHODS—Our study of two large families (USA Family R and Dutch Family A) with an
EPCAM deletion was carried out using each institution’s standard family study protocol. DNA
was extracted from peripheral blood and EPCAM deletion analysis was performed.
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RESULTS—Both families were found to harbor the same deletion at the 3′ end of EPCAM.
Analysis showed that the deletion originated from a common ancestor. Family R and Family A
members showed segregation of CRC with the presence of this EPCAM mutation. Compared with
classic LS, there were almost no extracolonic cancers.
CONCLUSIONS—Members of Family R and Family A, all with the same EPCAM deletion,
predominantly presented with CRC but no LS-associated endometrial cancer, confirming findings
seen in other, smaller, LS families with EPCAM mutations. In these EPCAM mutation carriers,
cancer surveillance should be focused on CRC.
INTRODUCTION
The Lynch syndrome (LS) predisposes to colon cancer and several extracolonic cancers, the
most common of which is endometrial cancer. These are caused by mutations in the DNA
mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2. A subset of families with
phenotypes consonant with LS, including microsatellite instability and abnormal MMR
immunohistochemistry have been found to harbor a deletion at the 3′ end of the gene
encoding epithelial cell adhesion molecule (EPCAM; previously referred to as TACSTD1)
(1–6). The tumors with EPCAM mutations showed high-level microsatellite instability;
immunohistochemistry tests disclosed a loss of MSH2 protein, with no identifiable mutation
in the MSH2gene (1,3). EPCAM mutations were found to cosegregate with the LS
phenotype in a considerable fraction (19%) of LS families that lacked MLH1/MSH2
mutations (3) and to account for at least 2.3% of explained MSH2-deficient families (5).
EPCAM is located immediately 5′ of MSH2 and deletion of its termination signal allows
transcription to follow through across the MSH2 promoter leading to promoter
hypermethylation and gene silencing. In EPCAM deletion-positive subjects, the risk of
developing colorectal cancer (CRC) was shown to be comparable to that of carriers of a
MSH2 mutation. However, their risk of developing endometrial cancer was lower than in
MSH2 mutation carriers, and appeared to be restricted to carriers of deletions that extend
close to the MSH2 gene (7).
Family R (Figure 1) is a large LS family that was referred to the Creighton research group
35 years ago by the proband’s surgeon, who knew that CRC was highly prevalent
throughout five generations of the family. Study of Family R contributed to the template for
the classic description of LS and it was the fourth hereditary CRC family studied by Dr
Lynch. Family R was first reported at a conference in 1976 (8), and further updated in 1977
(9). Repeated comprehensive DNA testing by several groups failed to find a mutation in a
MMR gene until EPCAM deletions were reported to cause LS (1).
In this study we show that Family R carries the same EPCAM mutation as Dutch Family A,
the first family in which a 3′ end EPCAM deletion was recognized as the cause of MSH2-
deficient tumors due to hypermethylation of the MSH2 promoter (1). These two families are
the largest common ancestor pedigrees reported to date. Analysis of their tumor spectrum is




This study was approved by the Institutional Review Boards of the institutions involved.
USA Family R—Contact was continually maintained with Family R through telephone
calls, correspondence, and personal contact through several educational family information
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services (FISs) (10). The FIS is comprised of a gathering of as many family members as
wish to attend the meeting so that they can benefit from an informal educational coverage of
the “family disease”, including its diagnosis, the significance of a deleterious germline
mutation, and its phenotypic features. It then deals with the patient’s risk of developing CRC
with focus upon targeted screening recommendations based upon a patient’s position in the
pedigree. The proband (Figure 1, III-4) and several other family members were instrumental
in gathering information from and distributing information to the family. Genetic counseling
was based upon the compelling evidence for a Mendelian autosomal dominant pattern of
CRC throughout the family in concert with its striking clinical and pathology features.
Given these findings, first-degree relatives of individuals who developed CRC were strongly
encouraged to undergo colonoscopy every other year starting at age 20–25 and then annually
beginning at age 40 (8,11–14). At the time of the FIS, the initial finding of a lack of
endometrial cancer risk had not yet been confirmed and patients were recommended
standard LS endometrial cancer surveillance and consideration of prophylactic
hysterectomy.
Following the discovery of MMR mutations in LS families in the mid-1990s (15–20), we
began DNA testing on the most genetically informative members of Family R, namely those
with early onset CRC and/or metachronous CRC; however, we were unable to identify a
MMR gene mutation.
In October 2009, the EPCAM mutation c.859-1462_* 1999del was identified in a member
of Family R (Figure 1, V-6). Shortly afterward, we held another FIS wherein > 70 Family R
members attended in order to learn about this new finding and how it might impact them.
Family members for whom we did not have a stored sample were invited to provide blood
for testing. Forty-seven DNA samples were tested for the EPCAM mutation. Another FIS
was held in March 2010 in order to provide individuals with their DNA test results in private
genetic counseling sessions. This FIS also gave other family members an opportunity to
provide a DNA sample for testing. All living relatives found it acceptable to include their
genotyping information in the pedigree.
Dutch Family A—The proband of the Dutch Family A (Figure 2) visited the outpatient
clinic for family cancer of the Radboud University Nijmegen Medical Centre, because he
developed two colorectal carcinomas at age 47. He was the first patient in whom a deletion
of the 3′ end of EPCAM was observed (1). This deletion was also detected in his son, who
visited our outpatient clinic because he developed an MSH2-deficient CRC at age 18. This
deletion was also present in three more distantly related family members affected with CRC,
who had been contacted by the proband and underwent genetic counseling and testing for
this mutation. After the pathogenicity of the deletion was proven, presymptomatic testing
was offered to other family members using routine procedures by which the information is
disseminated by contact persons within the family. Individuals in the pedigree were de-
identified to protect their privacy without loss of the scientific information.
Laboratory methods
Immunohistochemistry for the MMR proteins was performed as previously described (1). In
Family R, EPCAM deletion analysis was performed on DNA extracted from peripheral
blood using a commercially available MLPA (multiplex ligation-dependent probe
amplification kit; P072 version 6, MRC Holland, Amsterdam, The Netherlands) as per the
manufacturer’s instructions. This kit contains oligonucleotide probes targeting EPCAM
exons 3, 8, 9, and two probes in the intervening region between EPCAM and MSH2: one 3
kb downstream of EPCAM and one 2.5 kb upstream from the MSH2 gene. In Family A, the
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Overall, DNA testing for the EPCAM mutation in Family R showed that 22 individuals were
positive, 16 were obligate mutation carriers, and 42 were negative (Figure 1). Fifteen family
members received their results at the March 2010 FIS, and an additional 49 received their
results through scheduled telephone counseling sessions. Carriers of the mutation shared this
information with their children and siblings who had not been tested. Subsequently,
additional samples were submitted for testing and the results are pending.
Table 1 depicts the cancer spectrum in Family R in those who have lived to at least age 20
and have a risk of mutation carrier-ship of ≥25%. This table includes those who were tested
positive for EPCAM mutation, those who were tested negative, and those who were not
tested. When those not tested are excluded, all but one of the individuals with CRC either
tested positive or is an obligate gene carrier.
Noteworthy is the fact that 50 Family R members had CRC with a mean age at diagnosis of
49 years (range 20–76 years). It is of interest that, unlike other LS families, only a single
patient had endometrial cancer and this individual was found to be negative for the EPCAM
mutation. There were no cases of ovarian cancer. Three family members had small bowel
cancer; of these, one tested positive for the EPCAM mutation, one tested negative, and the
third has not been tested. The tumor tissue from the small bowel cancer from the confirmed
EPCAM mutation carrier was available and showed loss of MSH2 and MSH6 expression.
Three family members had upper uroepithelial tract cancer; none of them has been tested.
Dutch Family A
For the Dutch Family A, clinical data were collected for all family members who underwent
genetic testing (Table 2). All 10 patients with CRC were carriers of the mutation. The mean
age at diagnosis of their first CRC was 47 years (range 18–70 years). Within this group, the
only extracolonic cancers detected were one MSH2-deficient duodenal cancer, one MSH2-
proficient urothelial carcinoma, two breast, one lung, and one pancreas carcinoma. These
latter four tumors were not available for further analysis. No endometrial cancers were
observed.
Common ancestor
Both families share the 3′ end EPCAM deletion c.859-1462_* 1999del. Single nucleotide
polymorphism array-based genotyping showed that a large genomic region surrounding the
deletion (haploblock) was shared by members of both Family R and Family A (Figure 3).
These findings indicate that the EPCAM mutations in Family R and Family A originate
from a common ancestor. The same mutation has been detected in 15 other Dutch probands
(5,7).
DISCUSSION
The extended kindreds described here are among the largest reported in medical genetics.
The breadth and size of the kindreds, and the number of related cancers, is testament to the
potential impact of a single mutation event. Over the years, genetic epidemiology research
has resulted in a significant expansion of knowledge on what was initially termed the
“cancer family syndrome”, (9) subsequently called hereditary nonpolyposis CRC, and now
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referred to as LS (11,12,21). Specifically, diagnostic parameters such as the occurrence of
cancer of diverse anatomic sites, its pattern of cancer combinations, early age of cancer
onset, pathological features, MMR penetrance, accelerated carcinogenesis, and survival may
vary enormously within and between families. The Amsterdam Criteria (22,23) were
developed two decades ago in an attempt to better describe and define LS families.
However, only about 60% of families fulfilling the Amsterdam Criteria manifest MMR
germline mutations consonant with LS (24). A subset of the remaining 40% include familial
CRC type X (25), while the more recently discovered EPCAM mutation explains part of the
remainder (1–6).
Site-specific CRC and EPCAM
The tumors of EPCAM deletion carriers show loss of expression of MSH2 and MSH6, a
pattern also seen with MSH2 germline mutation carriers. Nowadays, the majority of clinical
laboratories that are testing for MMR gene mutations test for EPCAM deletions as relevant
probes for the EPCAM gene are included in the MLPA kit used for the analysis of MSH2
deletions. The medical and genetic literature shows that MSH2 mutation carriers develop
extracolonic cancers, especially endometrial cancer, more frequently than carriers of MLH1
mutations (3,11,12). Deletions in EPCAM result in hypermethylation and tissue-restricted
silencing of MSH2 (1), which is dependent on the expression pattern of the EPCAM gene.
This finding probably explains the rare incidence of extracolonic cancers in the subset of
EPCAM mutation carriers in both extended families described here and multiple other
families described earlier (7). There is little experimental evidence on the relative expression
of EPCAM in various tissues. We postulate that at least during early stages of endometrium
carcinogenesis, EPCAM is not sufficiently expressed and therefore the MSH2 promoter is
not efficiently silenced, leading to a lower endometrial cancer risk than observed in MSH2
mutation carriers. In our recent collaborative study of specific EPCAM deletion genotype/
phenotype correlations, no endometrial cancer was observed in 62 female EPCAM deletion
carriers with mutations distant from the MSH2 promoter (7). Endometrial cancer was
observed in only 3 out of 30 carriers with larger EPCAM deletions that extend close to the
MSH2 promoter. In line with this, the family history of the total 12 additional EPCAM
deletion families shows no endometrial cancers (6,26). Unspecified gynecologic cancers
were noted in only one of these families, which has a deletion extending close to the MSH2
promoter (6). A large collaborative study is needed to further refine the endometrial cancer
risk with respect to the size and location of the EPCAM deletion. Nevertheless, the absence
of endometrial cancer in the two large families of ancestral origin described here and the
additional 33 female carriers with the same deletion described earlier (7) is highly
significant and strongly supports the assumption that families with small EPCAM deletions
have no increased risk for endometrial cancer. This finding lends support to practice-
changing management for LS patients with such EPCAM deletions. Specifically, screening
could be focused exclusively on CRC. Therefore, women could be spared surveillance and
consideration for prophylactic hysterectomy (27).
Three cases of small bowel adenocarcinoma, two occurring in the duodenum and one in the
jejunum, were seen in Families R and A. Other small bowel cancers, located in the
duodenum and ileum, have been identified in EPCAM mutation carriers (1,4,7). The timing
and frequency of small bowel cancer surveillance in EPCAM mutation carriers require
further study before an informed recommendation can be made.
Genetic counseling implications
LS families with EPCAM mutations now have a rational explanation for their significantly
increased cancer susceptibility. Therefore, instead of receiving an “uninformative negative”
MSH2 mutation test result, they are given results based on a pathogenic EPCAM mutation.
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Family members found not to harbor the EPCAM mutation do not have an increased
lifetime risk for cancer and thus can follow general population screening guidelines.
Conversely, those found to have the EPCAM pathogenic mutation will be advised to follow
the high-risk LS CRC surveillance recommendations. Having a definitive diagnosis has
increased acceptance of LS cancer screening recommendations (11,12).
Limitations for implementing diagnosis and cancer control in LS
LS is frequently under-recognized due to small families, physicians not taking a detailed
family history for cancer, or unawareness by patients of their own family history (28).
Although routine microsatellite instability testing at the initiative of the pathologist in CRC
diagnosed before age 50 can significantly enhance recognition of LS patients (29), this
procedure has been implemented in only relatively few centers. In the next few years, many
evolving genetic and genomic technologies devoted to cancer risk assessment will reach our
daily clinical practice, heralding and finally implementing the era of personalized medicine
(30). It will be important for clinicians to recognize the oft en profound cancer control
potential when attention is paid to the family history including early age at cancer diagnosis
and, when necessary, referral is made to genetic centers that offer high levels of expertise for
DNA testing when appropriate. This permits the physician to apply appropriate surveillance
programs to patients who require this, and to avoid inappropriate surveillance in at-risk
family members who did not inherit the pathological allele. Family R and Family A, with
the identification of their EPCAM mutation, is one such example.
The presence of a small 3′ EPCAM deletion has resolved the high incidence of
microsatellite instability-high tumors in two large LS families that were unexplained for
decades. The lack of endometrial cancer in these families marks further understanding of the
differences in the LS phenotype that will lead to more effective cancer control. The
discovery of EPCAM deletions and their impact on hereditary cancer is likely the tip of the
proverbial iceberg with respect to mutations that affect known disease causing genes
indirectly. Large, well-characterized families as described here can be instrumental in
unraveling such novel genetic mechanisms, which will increase our understanding of gene
regulation and may provide a multitude of families with important information for
surveillance (11,12).
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WHAT IS CURRENT KNOWLEDGE
✓ Lynch syndrome is a complex disease with a wide phenotype caused by
mutations in several genes. Some of the variations seen in the Lynch
syndrome phenotype can be attributed to which gene is mutated. However,
the gene-specific risks for Lynch syndrome are still under investigation.
✓ Lynch syndrome’s cancer phenotype may differ due to colorectal cancer
(CRC) predominance with deficit of extracolonic cancer resulting from
deletion at the 3′ end of the epithelial cell adhesion molecular (EPCAM)
gene, resulting in transcription read-through with silencing of MSH2 through
hypermethylation of its promoter.
WHAT IS NEW HERE
✓ Epithelial cell adhesion molecule (EPCAM) mutation was identified in two
highly extended Dutch families, both of whom harbored the same deletion at
the 3′ end of EPCAM, showing that the deletion originated from a common
ancestor.
✓ Findings of almost exclusive colorectal cancer (CRC) with virtually no
extracolonic cancer show a likely paradigm change in cancer screening of
certain families with the EPCAM mutation.
✓ Lynch syndrome patients carrying this EPCAM deletion are not at increased
risk for the extracolonic cancers seen in Lynch syndrome. Therefore, cancer
control in this group should focus on CRC.
Lynch et al. Page 9














Pedigree of Family R. Numbers below the symbols refer to the age in years of last clinical
follow-up.
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Pedigree of Family A. The clinical data of the relatives that have not been tested are less
reliable than those of the tested subjects and the obligate carriers. For pedigree legend see
Figure 1. Ca, colorectal adenoma; Cx, cervix; EPCAM; epithelial cell adhesion molecule;
Eso, esophagus; Thy, thyroid; Ut, urothelial tract.
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EPCAM founder mutation. (a) Schematic representation of the epithelial cell adhesion
molecule (EPCAM) founder deletion seen in Families A and R. The deletion encompasses
exons 8 and 9 of the EPCAM gene but does not extend into the MSH2 promoter. (b)
Representation of Affymetrix SNP6.0 array data of the genomic region around EPCAM in
four Dutch Families (including Family A) and three members of USA Family R. Haplotypes
of chromosome 2 were derived from homozygous calls of the 75,933 single nucleotide
polymorphisms (SNPs) on this chromosome, and positions of discordant homozygous calls
(DHCs) were marked. The location of EPCAM is indicated by the box and line. For Family
A and Family R, there is a shared region, which includes EPCAM (boxed). Comparing the
Dutch family members and one member of Family R (the lane labeled “Merge 5 patients”)
there is a stretch of 2,186 SNPs (6.12 Mb) with only five DHCs, strongly indicating a
common ancestor. For the Dutch patients, there were two large stretches of 1,341 and 906
SNPs, without DHCs, separated by a single DHC. For Family R, there is a larger stretch of
shared SNPs compared with Dutch Family A members. This stretch is 17.22 Mb, 9,850
SNPs long with 81 DHCs. The larger shared haploblock seen in Family R would be
consistent with the founding of Family R in the United States by immigration of a single
Dutch EPCAM mutation carrier after origination of the deletion in the Netherlands.
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Table 1
Cancer spectrum of USA family R members age 20 + and syndrome risk ≥ 25%
Cancer sites EPCAM family genetic test results
Pos + OGCa Negative Not tested Total
Colon 22 1 27 50
Skin 2b 1 2 5
Small intestine 1c 1d 1c 3
Stomach 1c 0 1 2
Unknown primary 1 0 2 3
Breast 0 2 5c 7
Upper uroepithelial 0 0 3c 3
Lymphoma 0 0 3 3
Lung 0 0 2 2
Brain 0 0 2 2
Prostate 0 1 1 2
Pancreas 0 0 1 1
Testicle 0 0 1 1
Urinary bladder 0 0 1 1
Female organ? 0 0 1c 1
Endometrium 0 1 0 1
Leukemia 0 1 0 1
No cancer 13 29 201 243
Total individuals 36 37 250 323
EPCAM, epithelial cell adhesion molecule; OGC, obligate gene carrier.
a
Includes those tested positive plus Obligate Gene Carriers (child tested positive).
b
Both individuals also diagnosed with colon cancer.
c
One individual also diagnosed with colon cancer.
d
This individual also diagnosed with melanoma.
Of the 57 individuals tested, 20 are positive and 37 are negative.
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Table 2
Cancer spectrum of dutch family A members age 20 + and syndrome risk ≥25%
Cancer sites EPCAM family genetic test results
Pos + OGC* Negative Not tested Total
Colon 10 0 5 15
Skin 0 0 0 0
Esophagus 0 0 1 1
Duodenal 1a 0 0 1
Stomach 0 0 0 0
Unknown primary 0 0 0 0
Breast 2a 0 0 2
Upper urothelial tract 1b 0 0 1
Lymphoma 0 0 0 0
Lung 1 0 0 1
Brain 0 0 0 0
Prostate 0 0 0 0
Pancreas 1a 0 0 1
Testicle 0 0 0 0
Urinary bladder 0 0 0 0
Endometrium 0 0 0 0
Leukemia 0 0 0 0
Thyroid 0 1c 0 1
Cervix 0 1 0 1
No cancer 31 31 25 87
Total individuals 41 32 31 104
EPCAM, epithelial cell adhesion molecule; OGC, obligate gene carrier.
a
Individuals also diagnosed with colon cancer.
b
Also diagnosed with colorectal adenomas.
c
Also diagnosed with cervical cancer.
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